These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evidence-based decision making in managed care pharmacy. Penna P Manag Care Interface; 2002 May; 15(5):43-4. PubMed ID: 12024870 [No Abstract] [Full Text] [Related]
3. A call for fairness in formulary decisions. Levinson W; Laupacis A Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806 [No Abstract] [Full Text] [Related]
4. Using clinical evidence to manage pharmacy benefits: experiences of six states. Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357 [TBL] [Abstract][Full Text] [Related]
5. Should cost-effectiveness take the blame? McGregor M CMAJ; 2003 Jun; 168(12):1528; author reply 1528-9. PubMed ID: 12796326 [No Abstract] [Full Text] [Related]
6. Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures? Gafni A; Birch S CMAJ; 2003 Apr; 168(7):849-51. PubMed ID: 12668543 [No Abstract] [Full Text] [Related]
7. Evidence-based coverage decisions? Primum non nocere. McElwee NE; Ho SY; McGuigan KA; Horn ML Health Aff (Millwood); 2006; 25(4):W279-82. PubMed ID: 16757489 [TBL] [Abstract][Full Text] [Related]
8. Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary? Cross M Manag Care; 2007 Apr; 16(4):39-42. PubMed ID: 17491288 [No Abstract] [Full Text] [Related]
9. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications]. Garpenby P Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621 [No Abstract] [Full Text] [Related]
10. The P&T Society. Bootman L Manag Care Interface; 2006 Feb; 19(2):13, 15. PubMed ID: 16583504 [No Abstract] [Full Text] [Related]
11. Do drug formulary policies reflect evidence of value? Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886 [TBL] [Abstract][Full Text] [Related]
13. I why we need a PDL and how it works. Hauser H Tex Med; 2004 Apr; 100(4):7. PubMed ID: 15303483 [No Abstract] [Full Text] [Related]
14. The DERP: is it an effective methodology? Heaton AH Health Aff (Millwood); 2006; 25(4):W276-8. PubMed ID: 16757488 [TBL] [Abstract][Full Text] [Related]
15. The case for a value-based formulary: striving for total lowest net cost. Weart W; Bauman GR Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330 [TBL] [Abstract][Full Text] [Related]
16. Formularies: the role of pharmacy-and-therapeutics (P&T) committees. Summers KH; Szeinbach SL Clin Ther; 1993; 15(2):433-41; discussion 432. PubMed ID: 8519049 [TBL] [Abstract][Full Text] [Related]
17. Controlling the cost of branded drugs. Mandelker J Bus Health; 1993 Nov; 11(13):44-6, 48. PubMed ID: 10130506 [TBL] [Abstract][Full Text] [Related]
18. Antidementia agents: what is important in this class. Stefanacci RG; Cafiero AC Manag Care; 2005 May; 14(5 Suppl):11-6. PubMed ID: 15962832 [No Abstract] [Full Text] [Related]
19. Showing outcomes and proving value brings success. Fullerton DS; Atherly D; Sullivan SD Manag Care Interface; 2001 Jun; 14(6):63-5, 71. PubMed ID: 11432153 [TBL] [Abstract][Full Text] [Related]
20. Drug benefits in managed care: seeking ethical guidance from the formulary? Fins JJ J Am Geriatr Soc; 1998 Mar; 46(3):346-50. PubMed ID: 9514384 [No Abstract] [Full Text] [Related] [Next] [New Search]